Lexaria Bioscience (LEXX) it has received the necessary independent ethics board approval required for its contract research organization to begin to implement and execute human pilot study GLP-1-H25-5. The Study will compare an oral version of liraglutide, formulated from the DehydraTECH-processing of Saxenda to the conventional injected liraglutide. The Study is expected to be conducted with 8-10 healthy volunteers with the goals of demonstrating safety and pharmacokinetic performance in humans utilizing orally dosed DehydraTECH-liraglutide. If the Study results are positive, it could support a decision to investigate oral DehydraTECH-liraglutide in a future Phase I registered trial.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEXX:
- Lexaria’s Oral Drug Shows Promising Results Against Eli Lilly’s Injection
- Lexaria Bioscience announces partial results from GLP-1-H24-3 study
- Lexaria Bioscience’s Phase 1b study starts patient dosing, says H.C. Wainwright
- Lexaria Bioscience Initiates Promising Drug Study
- Lexaria Bioscience begins dosing for GLP-1 study #4
Questions or Comments about the article? Write to editor@tipranks.com